Congress funds $120M biopharmaceutical research hub—but who owns the discoveries?

What it does

This bill directs the National Institute of Standards and Technology (NIST) to award a $120 million grant or contract to establish a National Biopharmaceutical Manufacturing Center of Excellence. The center will conduct research, develop manufacturing technologies, train workers, and coordinate with universities, companies, and government agencies to strengthen U.S. biopharmaceutical production capacity and reduce dependence on foreign supply chains.

Why we flagged it

The bill establishes a federally funded research center under NIST to advance biopharmaceutical manufacturing science and workforce development. It is a straightforward infrastructure and R&D investment with national-security and economic-resilience framing, not a regulatory change, tax provision, or private carve-out.

What the text implies

• The center's intellectual property guidelines (subsection d) will determine whether innovations are publicly available or proprietary to the winning applicant, potentially creating a private monopoly on federally funded discoveries.
• Selection criteria (subsection b(4)(F)) prioritize applicants with co-investment from private sources, which may bias the award toward well-capitalized companies or partnerships over smaller innovators or purely academic institutions.
• The bill does not specify whether the center's research findings and best practices must be made freely available to all U.S. manufacturers or can be restricted to the center's partners, creating potential competitive advantage for the selected entity.
• Workforce training programs funded by the center may primarily benefit companies in the region where the center is located, creating geographic disparities in biotechnology talent development across the United States.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill funds public research infrastructure, workforce development, and supply-chain resilience in a strategically important sector. Citizens benefit from improved domestic pharmaceutical manufacturing capacity, reduced foreign dependency, worker training opportunities, and publicly accessible research findings. No direct restrictions on citizen rights or protections are imposed.

Who stands to gain

• biopharmaceutical manufacturers (large, medium, and small)
• pharmaceutical supply-chain companies
• institutions of higher education (research funding)
• the selected public-private partnership or consortium operator

Named in the bill

National Institute of Standards and Technology (NIST), National Biopharmaceutical Manufacturing Center of Excellence, Manufacturing USA institutes, institutions of higher education, pharmaceutical manufacturers, biotechnology sector

Where it stands

16 cosponsors: 9 Democrats, 7 Republicans.

• Nov 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 18, 2025 — Referred to House Committee on Science, Space, and Technology · Congress.gov: “Referred to the House Committee on Science, Space, and Technology”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $7,390,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Chrissy Houlahan, the sponsor, reported $539,500 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Hearth, Patio & Barbecue Association — $30,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.